Lyrica Titration
Start pregabalin at 50 mg three times daily or 75 mg twice daily (150 mg/day total), increase to 300 mg/day after 3-7 days, then increase by 150 mg/day every 3-7 days as tolerated up to a maximum of 600 mg/day. 1, 2
Standard Titration Schedule
The FDA-approved dosing provides straightforward titration due to pregabalin's linear pharmacokinetics 2:
- Initial dose: 50 mg TID or 75 mg BID (150 mg/day)
- First increase: After 3-7 days, increase to 300 mg/day (100 mg TID or 150 mg BID)
- Further titration: If inadequate pain relief at 300 mg/day, increase by 150 mg/day every 3-7 days
- Maximum dose: 600 mg/day (200 mg TID or 300 mg BID)
- Duration of adequate trial: 4 weeks 1
Critical caveat: Doses above 300 mg/day are not consistently more effective than 300 mg/day and carry significantly higher rates of adverse effects 1. Reserve dosing above 300 mg/day only for patients with ongoing pain who tolerate 300 mg/day well 2.
Renal Impairment Adjustments
Pregabalin is eliminated primarily by renal excretion—dose adjustment is mandatory in renal impairment. 2, 3 Use the Cockcroft-Gault equation to estimate creatinine clearance, then adjust according to this algorithm 2:
Dosing by Creatinine Clearance:
- CLcr ≥60 mL/min: Standard dosing (150-600 mg/day, BID or TID)
- CLcr 30-60 mL/min: Reduce dose by 50% (75-300 mg/day, BID or TID)
- CLcr 15-30 mL/min: Reduce dose by 75% (25-150 mg/day, QD or BID)
- CLcr <15 mL/min: Reduce dose by approximately 85% (25-75 mg/day, QD)
Hemodialysis Patients:
Adjust the daily dose based on renal function as above, plus administer a supplemental dose immediately after each 4-hour hemodialysis treatment 2:
- 25 mg QD regimen: supplement with 25-50 mg post-dialysis
- 25-50 mg QD regimen: supplement with 50-75 mg post-dialysis
- 50-75 mg QD regimen: supplement with 75-100 mg post-dialysis
- 75 mg QD regimen: supplement with 100-150 mg post-dialysis
Important: Pregabalin clearance is directly proportional to creatinine clearance (56-58% correlation), meaning AUC and half-life increase substantially with declining renal function 3. A 50% dose reduction is recommended for each additional 50% decrease in creatinine clearance 3.
Geriatric Patients
Consider lower starting dosages and slower titration in older patients 1. While the guidelines don't specify exact geriatric doses, the rationale is clear:
- Older adults have age-related reductions in renal function even with "normal" creatinine
- Higher vulnerability to dose-dependent adverse effects (dizziness, somnolence, cognitive dysfunction) 4, 5, 6
- Greater risk of falls and peripheral edema 7
Practical approach for elderly patients: Start at 25-50 mg at night, uptitrate in weekly increments based on tolerability 6. Always calculate creatinine clearance rather than relying on serum creatinine alone, as older adults may have reduced muscle mass masking renal impairment.
Key Clinical Pitfalls
Dizziness and sedation are dose-dependent and can be minimized by starting low and titrating cautiously 1. These effects typically emerge early in treatment but may improve with continued use.
Do not assume standard dosing is safe in elderly patients or those with borderline renal function—even mild renal impairment (CLcr 50-60 mL/min) requires dose reduction 2. The pharmacokinetic data show pregabalin half-life extends from 6.3 hours in normal renal function to significantly longer durations with impairment 3, 8.
Weight gain and peripheral edema are dose-related, so keeping patients at the lowest effective dose (often 300 mg/day) improves tolerability 6.
Pregabalin offers faster onset of analgesia compared to gabapentin because the initial 150 mg/day dose is often efficacious and requires less time to reach therapeutic levels 1. The median time to onset of pain relief is 1.5-3.5 days versus >4 weeks with placebo 4.